Oculis Holding AG Files 6-K with Q2 2024 Financials
Ticker: OCSAW · Form: 6-K · Filed: Aug 27, 2024 · CIK: 1953530
| Field | Detail |
|---|---|
| Company | Oculis Holding Ag (OCSAW) |
| Form Type | 6-K |
| Filed Date | Aug 27, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financials, sec-filing, 6-K
TL;DR
Oculis Holding AG dropped Q2 2024 financials, showing share comp and operating expenses.
AI Summary
Oculis Holding AG filed a 6-K report on August 27, 2024, detailing financial information as of June 30, 2024. The filing includes data on share-based compensation, conditional share capital for earnout options, and other operating expenses for the period from January 1, 2024, to June 30, 2024. It also references historical data from December 31, 2023, and March 2, 2023, related to share premium, issued capital, and an acquisition.
Why It Matters
This filing provides investors with an update on Oculis Holding AG's financial position and operational expenses for the second quarter of 2024, crucial for assessing the company's performance and future outlook.
Risk Assessment
Risk Level: low — This is a routine 6-K filing providing financial updates and does not indicate any immediate or significant new risks.
Key Numbers
- Q2 2024 — Reporting Period (Financial data pertains to this period)
- 2024-01-01 to 2024-06-30 — Period for Expenses (Share-based compensation and other operating expenses are detailed for this six-month period.)
Key Players & Entities
- Oculis Holding AG (company) — Filer of the report
- 20240630 (date) — Reporting period end date
- 20240827 (date) — Filing date
- EuropeanBiotechAcquisitionCorp (company) — Mentioned in relation to a past event on 2023-03-02
FAQ
What specific financial figures are provided for the period ending June 30, 2024?
The filing references data points such as ShareBasedCompensationPersonnelExpenseMember, ConditionalShareCapitalForEarnoutOptionsMember, and OtherOperatingExpensesMember for the period January 1, 2024, to June 30, 2024.
What is the significance of the date March 2, 2023, mentioned in the filing?
The date March 2, 2023, is associated with 'EuropeanBiotechAcquisitionCorpMember', suggesting a past event or transaction involving this entity.
What type of financial information is typically included in a 6-K filing?
A 6-K filing is used to report information that the company has made or will make public outside of the U.S., such as material events, earnings statements, or financial updates.
What does 'ConditionalShareCapitalForEarnoutOptionsMember' refer to?
This likely refers to share capital set aside or reserved for potential issuance as part of earnout agreements, often related to acquisitions.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Filing Stats: 588 words · 2 min read · ~2 pages · Grade level 12.4 · Accepted 2024-08-27 16:01:20
Filing Documents
- ocs-20240630.htm (6-K) — 127KB
- ocs-ex99_1.htm (EX-99.1) — 1725KB
- ocs-ex99_2.htm (EX-99.2) — 517KB
- ocs-ex99_3.htm (EX-99.3) — 200KB
- ocs-ex99_4.pdf (EX-99.4) — 858KB
- ocs-ex99_5.pdf (EX-99.5) — 613KB
- img187686630_0.jpg (GRAPHIC) — 11KB
- img189533672_0.jpg (GRAPHIC) — 8KB
- 0000950170-24-100990.txt ( ) — 12320KB
- ocs-20240630.xsd (EX-101.SCH) — 1156KB
- ocs-20240630_htm.xml (XML) — 1574KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. OCULIS HOLDING AG Date: August 27, 2024 By: /s/ Sylvia Cheung Sylvia Cheung Chief Financial Officer